Alnylam Pharmaceuticals Inc (ALNY)vsIncyte Corporation (INCY)
ALNY
Alnylam Pharmaceuticals Inc
$303.05
-0.19%
HEALTHCARE · Cap: $37.76B
INCY
Incyte Corporation
$102.38
+1.13%
HEALTHCARE · Cap: $21.68B
Smart Verdict
WallStSmart Research — data-driven comparison
Incyte Corporation generates 25% more annual revenue ($5.36B vs $4.29B). INCY leads profitability with a 26.7% profit margin vs 12.6%. INCY appears more attractively valued with a PEG of 0.36. INCY earns a higher WallStSmart Score of 80/100 (A-).
ALNY
Strong Buy65
out of 100
Grade: B-
INCY
Exceptional Buy80
out of 100
Grade: A-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.4%
Fair Value
$2372.19
Current Price
$303.05
$2069.14 discount
Margin of Safety
+83.4%
Fair Value
$593.92
Current Price
$102.38
$491.54 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 54 in profit
Revenue surging 96.4% year-over-year
Strong operational efficiency at 23.0%
Growing faster than its price suggests
Earnings expanding 83.8% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Every $100 of equity generates 26 in profit
Keeps 27 of every $100 in revenue as profit
Areas to Watch
0.0% earnings growth
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 37.6x book value
No major concerns identified
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on PEG Ratio, Return on Equity, Revenue Growth. Revenue growth of 96.4% demonstrates continued momentum. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : INCY
The strongest argument for INCY centers on PEG Ratio, EPS Growth, Debt/Equity. Profitability is solid with margins at 26.7% and operating margin at 25.6%. Revenue growth of 20.9% demonstrates continued momentum.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, Debt/Equity, P/E Ratio. A P/E of 70.9x leaves little room for execution misses.
Bear Case : INCY
No major red flags identified for INCY, but monitor valuation.
Key Dynamics to Monitor
INCY carries more volatility with a beta of 0.79 — expect wider price swings.
ALNY is growing revenue faster at 96.4% — sustainability is the question.
INCY generates stronger free cash flow (359M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
INCY scores higher overall (80/100 vs 65/100), backed by strong 26.7% margins and 20.9% revenue growth. ALNY offers better value entry with a 86.4% margin of safety. Both earn "Exceptional Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Incyte Corporation
HEALTHCARE · BIOTECHNOLOGY · USA
Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?